Abeona Therapeutics Inc. (ABEO) Given Buy Rating at Jefferies Group LLC
Jefferies Group LLC reaffirmed their buy rating on shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) in a research note issued to investors on Wednesday morning. Jefferies Group LLC currently has a $28.00 price target on the biopharmaceutical company’s stock. Jefferies Group also issued estimates for Abeona Therapeutics’ Q4 2017 earnings at ($0.12) EPS, FY2017 earnings at ($0.59) EPS, FY2018 earnings at ($0.71) EPS, FY2019 earnings at ($0.19) EPS, FY2020 earnings at $0.57 EPS and FY2021 earnings at $1.97 EPS.
ABEO has been the topic of several other reports. Zacks Investment Research lowered shares of Abeona Therapeutics from a hold rating to a sell rating in a report on Tuesday, August 22nd. HC Wainwright reiterated a buy rating and issued a $30.00 target price (up from $20.00) on shares of Abeona Therapeutics in a report on Monday, October 9th. Royal Bank Of Canada started coverage on shares of Abeona Therapeutics in a report on Thursday, September 14th. They issued an outperform rating and a $23.00 target price on the stock. Maxim Group set a $17.00 target price on shares of Abeona Therapeutics and gave the stock a buy rating in a report on Tuesday, August 29th. Finally, Cantor Fitzgerald reiterated a buy rating and issued a $21.00 target price on shares of Abeona Therapeutics in a report on Friday, October 6th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $26.10.
Abeona Therapeutics (NASDAQ:ABEO) remained flat at $$16.15 on Wednesday. The company’s stock had a trading volume of 501,000 shares, compared to its average volume of 623,707. Abeona Therapeutics has a 12-month low of $4.05 and a 12-month high of $22.75.
Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.05. The company had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.22 million. Abeona Therapeutics had a negative net margin of 2,946.58% and a negative return on equity of 27.69%. equities research analysts expect that Abeona Therapeutics will post -0.66 EPS for the current fiscal year.
Several hedge funds have recently modified their holdings of ABEO. State of Wisconsin Investment Board bought a new stake in shares of Abeona Therapeutics during the second quarter worth $122,000. Rhumbline Advisers bought a new stake in shares of Abeona Therapeutics during the second quarter worth $190,000. Bank of New York Mellon Corp increased its position in shares of Abeona Therapeutics by 125.8% during the first quarter. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company’s stock worth $210,000 after acquiring an additional 23,358 shares in the last quarter. Schwab Charles Investment Management Inc. bought a new stake in shares of Abeona Therapeutics during the second quarter worth $264,000. Finally, California State Teachers Retirement System bought a new stake in shares of Abeona Therapeutics during the second quarter worth $275,000. 36.34% of the stock is owned by institutional investors.
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.